UM Research Repository
metadata only
CC BY-NC-ND 4.0
MAGEB2 antibody as potential diagnostic and predictive tool in the progression of oral cancer
Introduction: Oral squamous cell carcinoma (OSCC) represents more than 90% of all oral cancer. Despite advances in diagnostic and therapeutic modalities, mortality and morbidity rates have not improved in the last decade. Hence, alternative diagnostic and therapeutic approaches are urgently needed.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)#1150752
- Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma#1245356
- Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy#867175
- Estudo molecular de papilomavírus humano em lesões de carcinoma espinocelular bucal#946222
- ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC#1307548
Record · ID 1360825
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive